Publications by authors named "A R Prickett"
Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease that causes pain and fatigue, reduces physical function, and negatively impacts health-related quality of life (HRQoL). In the phase III BE OPTIMAL and BE COMPLETE studies, bimekizumab demonstrated clinical efficacy and meaningful improvements in patient-reported outcome (PRO) measures in biologic disease-modifying antirheumatic drug (bDMARD)-naïve patients, and those who had prior inadequate response/intolerance to tumor necrosis factor inhibitors (TNFi-IR).
Objectives: To examine the association between achieving increasingly stringent clinical disease control criteria and improvements in PRO measures in patients with active PsA receiving bimekizumab.
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of bimekizumab, a drug targeting specific proteins in the immune system, compared to other treatments for Psoriatic Arthritis (PsA) through a network meta-analysis.
- A systematic review of randomized controlled trials identified 41 studies involving 22 different biologic and targeted synthetic DMARDs to analyze their outcomes at 12-24 weeks.
- Results indicated that bimekizumab performed well in achieving minimal disease activity and other response measures, ranking highly for both new and experienced patients, with a safety profile similar to other treatments, making it a promising option for PsA patients.
Article Synopsis
- The study aimed to compare patient-reported outcomes (PROs) between newly diagnosed patients with psoriatic arthritis (PsA) who achieved minimal disease activity (MDA) in their first year and those who did not over a three-year period.
- Researchers categorized patients into three groups based on their MDA status at the 9 and 12-month marks, then analyzed their PROs using statistical models.
- Results showed that patients who did not reach MDA in the first year had significantly worse health, higher functional impairment, more pain and fatigue, and increased anxiety and depression over the follow-up period compared to those who maintained MDA.
Dopa decarboxylase (DDC) synthesizes serotonin in the developing mouse heart where it is encoded by , a tissue-specific paternally expressed imprinted gene. shares an imprinting control region (ICR) with the imprinted, maternally expressed (outside of the central nervous system) gene on mouse chromosome 11, but little else is known about the tissue-specific imprinted expression of . Fluorescent immunostaining localizes DDC to the developing myocardium in the pre-natal mouse heart, in a region susceptible to abnormal development and implicated in congenital heart defects in human.
View Article and Find Full Text PDF